Articles tagged with Drug Resistance
Researchers at Duke-NUS Medical School have designed armoured immune cells that can target hepatocellular carcinoma, a common type of primary liver cancer, without being affected by immunosuppressive drugs used to prevent organ rejection. The T cells remain effective for up to four days before regaining sensitivity to the drugs.
Scientists at Wits University infected mosquitoes with human malaria and identified a new chemical compound that shows promise in treating the disease. The study, published in Nature Communications, aimed to develop a drug that can block both human-to-mosquito transmission and mosquito-to-human transmission.
A new study published in Sports Medicine finds that resistance training has similar benefits for older women and men, with women achieving greater relative increases in lower body strength. The research suggests that trainers should program differently for each sex to maximize training benefits.
Researchers discover new mutations in malaria parasite that enhance resistance to sulfadoxine-pyrimethamine, a key preventive drug. These mutations are already widespread in Africa and Asia, threatening efforts to use the drug to prevent malaria in vulnerable groups.
Researchers have discovered that free-floating circular DNA fragments called ecDNA form in cancer cells and drive gene amplification to generate drug resistance. Combining chemotherapeutic drugs with molecules that prevent ecDNA formation can inhibit its emergence and reduce drug resistance.
Researchers found that chromothripsis breaks up chromosomes, leading to the formation of rearranged genomes and extra-chromosomal DNA that promotes cancer cell growth and drug resistance. This phenomenon enables cancer cells to evade treatment and become more aggressive.
Researchers at Cincinnati Children's Hospital Medical Center have discovered a novel method to boost the effectiveness of mTOR inhibitors against acute myeloid leukemia (AML) by targeting alternative signaling pathways. The study suggests using a combination therapy that combines an mTOR inhibitor with other drugs inhibiting CDK9, c-My...
Researchers found that reduced amounts of p120ctn contribute to resistance in cancers with high EGFR levels, leading to poorer treatment outcomes. Testing for p120ctn levels may help clinicians identify patients at risk for therapy resistance or relapse.
A subcutaneous injection of teclistamab elicits responses in 74% of patients with relapsed/refractory multiple myeloma, offering a promising treatment option for patients with poor prognoses. The study's results suggest that teclistamab takes a similar approach to cellular therapies but is more convenient and faster to administer.
New research suggests that dolutegravir, a widely used 'wonder drug' for HIV treatment, may not be as effective in patients with resistant strains of the virus. The study found that individuals with efavirenz-resistant mutations were less likely to achieve viral suppression when treated with dolutegravir.
Researchers at Charité and Tel Aviv University are investigating the causes of drug tolerance in invasive fungal pathogens. They aim to identify molecular pathways that explain this phenomenon and develop new treatments for life-threatening fungal infections.
A new University of Colorado Boulder study sheds light on CDK7's role in controlling cell growth and transcription, potentially leading to new therapies for hard-to-treat cancers and rare developmental disorders. The findings suggest that CDK7 inhibitors could have distinct therapeutic advantages and result in more selective and less d...
Purdue University engineers have developed a microfluidic device that allows scientists to test drugs on multiple tumor cell subtypes, revealing new insights into drug resistance. The technology mimics the behavior of pancreatic cancer cells within a tumor, enabling researchers to identify effective treatment strategies.
Researchers have developed a new cancer-specific anticancer drug that can prevent drug resistance and reduce side effects. The drug is designed to release an anticancer agent along with a drug-resistance inhibitor in cancer cells, effectively treating cancers without recurrence or treatment failure.
Researchers from RUDN University have developed a novel domino reaction for synthesizing chromenoisoquinolineamine derivatives, which showed promising antitumor activity against cancer cells, including drug-resistant strains. The new compounds were found to be toxic to tumor cells and efficient even at low concentrations.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab. In a non-Hodgkin's lymphoma mouse model, the treatment substantially increased rituximab binding and antibody-dependent cellular cytotoxicity activity, resulting in significant tumor growth delay.
Researchers have developed a new hyperpolarisation technique to monitor cancer drug efficacy, potentially replacing tissue biopsies. The method detects biomarkers like FOXM1, indicating drug resistance in ER-positive breast cancer.
A new potential drug treatment has been discovered for a type of lung-cancer. Researchers have found that combining osimertinib with linsitinib can cure or delay tumor recurrence in EGFR-mutated lung cancer, even in AXL-low expressing tumors.
A Duke University-led team has discovered how malaria parasites can survive fevers by producing a special lipid molecule and binding to heat shock proteins. This could lead to new ways to fight resistant strains of the disease. The findings also suggest caution when using fever reducers with artemisinin-based compounds.
Researchers at the University of Pittsburgh have discovered 'repliclones', large clones of HIV-infected cells that produce infectious virus particles, which can cause persistent viremia despite adherence to therapy. This finding has significant clinical implications and highlights a key barrier to developing a true cure for HIV.
Scientists at UT Austin identified a protein that promotes DNA damage in BRCA 1/2-mutated cancer cells, making them resistant to PARP inhibitors. The finding may help create more effective treatment plans for patients with these cancers.
Hundreds of thousands of UK patients are self-medicating with illegal cannabis-based products due to limited prescription availability. Researchers found that concerns about a perceived lack of scientific evidence and resistance from the medical profession hinder prescribing, despite substantial evidence of effectiveness in various dis...
A recent study examined the pharmacist's role in HIV care in France, revealing that only 40% of pharmacists systematically offer online patient medication files to people living with HIV. The survey also found that 7% of those who were offered medication interviews felt well taken care of.
Scientists from the University of Edinburgh have made a groundbreaking discovery that fungal cells can develop drug resistance through epigenetic changes, without altering their DNA sequence. This finding has the potential to revolutionize the management of fungal infections in plants and humans.
Researchers at USP and UNICAMP discovered eight novel polyphenols with anti-cancer properties in Brazilian red propolis. Two substances isolated from the rarest type of propolis significantly reduced proliferation of ovarian, breast, and brain cancer cells.
Researchers developed a novel drug delivery system that significantly enhances the effectiveness of treatment for melanoma. The system uses a biocompatible and biodegradable polymer to deliver two proven medications simultaneously at the tumor site, resulting in longer-lasting therapeutic effects and lower dosages.
Researchers used magnetic resonance elastography to detect changes in the hippocampus of patients with mesial temporal lobe epilepsy, which is resistant to medication. The study found that MRE can improve early detection and characterization of the disease.
Researchers have identified the human immune system's Achilles heel for a new, effective drug against Candida auris. The fungus is especially dangerous for people with compromised immunity and can be resistant to many disinfectants and fungicides.
Researchers at Children's Hospital of Philadelphia have developed a new treatment that shows long-term remissions in 80% to 100% of mice with drug-resistant or high-risk solid tumors. The treatment is less toxic than conventional chemotherapy, with fewer side effects.
A team of researchers at the Medical University of South Carolina has identified a critical player in resistance to targeted therapy in lung cancer. The protein NRP2b was found to drive resistance in non-small cell lung cancer cells that had become resistant to therapy, and inhibiting it caused the death of these cells.
Researchers adapted principles of quantum control to calculate alternative interventions for infection and cancer. They developed a mathematical algorithm that can design and speed up specific interventions to prevent or overturn drug resistance, offering a promising approach to defeating drug-resistant diseases.
Scientists developed an injectable HIV drug that blocks infection and provides extended viral suppression with lower doses and reduced side effects. The drug, CPT31, has great potential to help patients with drug resistance and those who would benefit from a longer-acting treatment option.
A new study suggests that repurposing cancer drugs to target human enzymes could lead to effective treatments for COVID-19, while reducing the risk of drug resistance. This approach has the potential to save years of research and millions of dollars in development costs.
A new computational model called TransComp-R has been developed to improve the translation of drugs from animal studies to human clinical trials. The model identified an overlooked biological mechanism possibly responsible for a patient's resistance to infliximab, a drug for inflammatory bowel diseases.
Researchers have discovered a new broad-spectrum method to treat human herpes viruses by targeting their physical properties rather than proteins. This approach prevents genes from leaving the virus and infecting cells, making it effective against resistant strains.
Researchers developed a stable 'mirror-image' peptide that effectively blocks the interaction between TIGIT and its ligand PVR, inhibiting tumor growth and metastasis. This approach offers an alternative point of attack for cancer immunotherapy, potentially outperforming existing anti-PD-1 therapy.
Researchers found that a low-dose combination of four inhibitors is more effective in treating NSCLC with EGFR mutation. The therapy, called MLD, inhibits the action of multiple proteins in the same signaling pathway, blocking cell proliferation and tumor growth.
Researchers discovered resistance to tumor inhibitors arises from gradual adaptation to selective pressures, providing opportunity for effective therapies. The study advances in evolution of resistance and offers evolutionary-informed therapies for future treatments.
Researchers analyzed 442 AML samples to identify immune classes that predict drug resistance and response to immunotherapy. IFN-γ-dominant AML patients showed strong responses to flotetuzumab and improved survival rates, highlighting the potential for T cell-targeting therapies.
Researchers at UCLA Jonsson Comprehensive Cancer Center found that combining toll-like receptor 9 agonists and NKTR-214 with PD-1 blockade can induce a potent immune reaction against resistant tumors. This combination therapy is being assessed in human clinical trials to improve cancer immunotherapy outcomes.
Myeloma Drug Sensitivity Testing (My-DST) uses liquid biopsies to test drug effectiveness on patient samples. The approach shows promise in predicting real patient responses, and may guide drug development for multiple myeloma treatment.
Researchers will sequence parasitic worm genomes to develop genetic tools for monitoring and tracking resistance, leading to new therapies. Two projects focus on river blindness and fascioliasis, causing devastating illness in millions of people globally.
Researchers found that combining rosiglitazone, a popular but abandoned diabetes treatment, with another drug called Compound A can enhance its effectiveness while reducing side effects such as weight gain and fluid retention. The study suggests that using lower doses of rosiglitazone may be sufficient to achieve similar results.
Scientists have discovered that malaria parasites have an intrinsic clock controlling their invasion of human cells. This finding opens up new avenues for treating the disease by disrupting its biological rhythms.
A study published in JAMA Network Open found that more than half of Americans starting highly regulated opioids may be receiving inappropriate treatment. The research team used pharmacy and medical claims data to identify nearly 300,000 instances of prescriptions for medications reserved for people with opioid tolerance. However, less ...
Researchers have discovered a new antiviral drug called EIDD-2801 that could change the way doctors treat COVID-19. The drug has shown promise in reducing lung damage and has been found to be effective in mice infected with SARS-CoV-2.
Researchers have discovered a new drug, FL118, that effectively treats and reverses treatment resistance in advanced multiple myeloma. The drug has shown promise in treating cancer cells from both newly diagnosed and relapsed or treatment-resistant patients.
Engineers have developed a method to predict which mutations will occur in people, making it easier to create effective pharmaceuticals. The researchers used algorithms similar to those used in chemical physics to model how evolution works and found that biased random events play a big part in the evolution of resistance in leukemia.
A new mass cytometry technique has identified key proteins in blood cancer cells, revealing why some cells are resistant to standard anti-cancer drugs. The research team hopes to apply this protocol to clinical trials to better understand why some cancers are resistant to therapies and match patients with more effective treatments.
Researchers identified a gene, CELSR2, associated with glucocorticoid resistance in leukemia cells. A new drug, venetoclax, may reverse resistance by inhibiting a cell death pathway. The findings suggest combining venetoclax with current therapy could improve ALL chemotherapy effectiveness.
Researchers discovered a new function of neurofibromatin, directly repressing estrogen receptor-alpha expression and causing treatment resistance in ER+ breast cancer. A combination therapy of SERD and MEK inhibitor was shown to be effective in animal models and is being tested in clinical trials.
The Pangaia project at Bielefeld University is developing new algorithms to analyze genomic data for biomedicine, enabling faster detection of infectious strains and hereditary diseases. Researchers can compare a single genome with thousands of others in a single step, highlighting similarities and differences.
Researchers discover potential superbug-killing compound AB569 that targets priority pathogens and additional bacteria causing foodborne illness. The compound has shown promising results in treating a wide range of infections, including those caused by Pseudomonas aeruginosa.
Researchers have identified two leukemia drugs that could be used to treat lung cancer patients with triple mutant EGFR, a type of non-small cell lung cancer. The drugs, gilteritinib and midostaurin, were found using a new live cell-based method developed by the University of Toronto team.
Researchers at KAIST have discovered mechanisms that fuel a 'domino effect' in cancer drug resistance, enabling failed responses to paclitaxel to speed up the evolution of resistance to other drugs. The study suggests a new strategy for improving second-line cancer treatment.
Researchers discovered that combining alectinib with EGFR-inhibitors prevents CNS metastasis progression in mouse model. This combination treatment overcomes alectinib resistance, offering potential novel therapies for NSCLC and secondary cancers.
Researchers at the Francis Crick Institute have discovered the mechanism behind HIV's resistance to a widely-prescribed group of drugs. By exploring the structure of integrase using cryo-electron microscopy, they found that the virus can weaken the bond between the drug and its target, enabling its key enzyme to work again.
Researchers at Florida State University College of Medicine have discovered the mechanism responsible for how two widely used antiviral drugs inhibit viruses, including HIV and hepatitis B. This breakthrough could lead to the development of more potent and effective treatments for millions of people worldwide.
A Brazilian research team identified the presence of mutant p53 protein clusters in chemotherapy-resistant glioblastoma cells, which can lead to drug resistance. The study found that these clusters are organized in a way that makes them resistant to temozolomide, a common treatment for the disease.
Researchers discovered that Kelch13 protein mutations can lead to parasite resistance by reducing hemoglobin uptake and ART activation. The findings provide critical insights into the development of more effective antimalarial treatments.